Imanivec (Imatinib)

Imatinib is a targeted therapy that inhibits specific tyrosine kinases involved in certain cancers.

• Chronic myeloid leukemia (CML): improves survival and achieves disease control.
• Gastrointestinal stromal tumor (GIST): reduces tumor growth and lowers recurrence risk.
• Other BCR‑ABL positive leukemias: provides disease control in eligible patients.

• Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, stabilising them in an inactive conformation. This blocks downstream signaling pathways that drive cell proliferation and survival, leading to apoptosis of malignant cells that depend on these kinases.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling, especially around the ankles.
• Muscle cramps: intermittent tightness or pain.
• Fatigue: general tiredness.
• Diarrhea: loose stools.
• Rash: skin irritation or redness.

Serious or Rare Side Effects

• Neutropenia: marked reduction in white blood cells.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: signs of reduced heart function.
• Severe fluid retention: rapid weight gain or pleural effusion.
• Hemorrhage: abnormal bleeding.
• Interstitial lung disease: breathing difficulties and cough.

Before initiating therapy, clinicians should evaluate baseline health status and monitor patients regularly.

• Blood count monitoring: perform complete blood counts to detect cytopenias.
• Liver function assessment: check hepatic enzymes periodically.
• Cardiac evaluation: assess heart function in patients with pre‑existing cardiac disease.
• Infection vigilance: avoid use in patients with active severe infections.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Warfarin: increased anticoagulant effect, risk of bleeding.

Moderate Interactions (Monitor Closely)

• Other tyrosine‑kinase inhibitors: additive toxicity risk.
• Diuretics: may exacerbate fluid retention.
• QT‑prolonging agents: monitor cardiac rhythm.
• Vaccines (live attenuated): assess timing relative to therapy.